Legend Biotech Corporation has announced new long-term clinical and translational data for its CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) therapy from the CARTITUDE-1 and CARTITUDE-4 studies in patients with relapsed or refractory multiple myeloma. In triple-class-exposed patients who had received three prior lines of therapy, a median progression-free survival of 50.4 months was observed following a single infusion of CARVYKTI®. Additionally, 80% of patients with standard-risk cytogenetics in the CARTITUDE-4 study remained progression-free and off treatment at 30 months after a single infusion. The results were presented at the American Society of Hematology $(ASH)$ 2025 annual meeting. Legend Biotech also presented first-in-human clinical data for its allogeneic CAR-T candidate LUCAR-G39D in adults with relapsed or refractory B-cell non-Hodgkin lymphoma. The study demonstrated a manageable safety profile and encouraging antitumor activity, with an overall response rate of 75% and a complete response rate of 37.5% among treated patients. No dose-limiting toxicities, immune effector cell-associated neurotoxicity syndrome, or graft-versus-host disease were reported. These results were also presented at ASH 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598064-en) on December 06, 2025, and is solely responsible for the information contained therein.
Comments